Alcidion Group Limited · ASX:ALC
Alcidion — Investor Presentation (December 2021)
43 slides from Alcidion's investor presentation, Dec 7, 2021
Slide 1: Transformational Acquisition & Capital Raising Presentation
Transformational Acquisition & Capital Raising Presentation 7 December 2021
Slide 2: Executive Summary
rs ALCIDION r | Executive Summa :
Slide 3: Modern, Modular EPR
“Acquiring Silverlink Software is strategic and transformational for Alcidion. It will allow us to leverage the capability of the Miya Precision platform to ultimately deliver a cloud-native, modern and modular EPR1 to rival major global incumbents” - Kate Quirke (Alcidion Group Managing Director) A
Slide 4: Executive Summary
Executive Summary • Acquiring Silverlink Software (Silverlink), one of the largest and few remaining specialist PAS1 providers servicing the UK NHS, with flagship Patient Case System (PCS) product • A PAS is a foundation of hospital IT systems capturing patient and attendance information to facilita
Slide 5: Executive Summary
Executive Summary • Alcidion, as part of a Consortium led by Leidos Inc, have signed a major healthcare IT project with the Major Contract Commonwealth of Australia to capture data and support clinical decision making with • $23.3M initial TCV over 6 years with $3.0M expected to be recognised in FY2
Slide 6: Overview of Alcidion
rs ALCIDION r | Overview of Alcidio
Slide 7: Alcidion – a Snapshot
Alcidion – a Snapshot • Alcidion has a simple purpose: To transform healthcare with Click Here to Play smart, intuitive technology solutions that improve the efficiency Introductory Video and quality of patient care in healthcare organisations, worldwide • Focus on providing tools to clinicians to e
Slide 8: Workflow of Patient Information
Workflow of Patient Information Seamlessly inter-operating with existing systems or stand alone, Alcidion enables clinicians to make better decisions • ALC products integrate and inter-operate with not only major EPR/EMR systems but also “specialist system” applications to create a unified platform,
Slide 9: Product Proposition – a clinician focused offering
Product Proposition – a clinician focused offering Challenges Approach Patient Safety • Unlock value in existing IT investments using open standards with modular approach Real-time critical notifications to clinicians reduce cognitive load to minimise clinical risk & prevent poor patient outcomes •
Slide 10: Growth Focus in FY22 and Beyond
Growth Focus in FY22 and Beyond Accelerating expansion in line with the strategy to become a global leader in healthcare technology 1 All (Markets): Upsell Miya Precision (or other modules) to existing Alcidion customers 2 All: Win new Miya Precision installs 3 UK: Listed on Procurement Frameworks (
Slide 11: Acquisition Rationale
rs ALCIDION Gi ' Acquisition Ratio 1a
Slide 12: Acquisition of Silverlink – Aligned with Strategy
Acquisition of Silverlink – Aligned with Strategy • Provides Alcidion with a PAS capability (a core part of hospital IT) thereby expanding the overall product offering whilst providing a strategic pathway to developing a cloud-native, modern and modular EPR solution Expands Product 1 • Expands addre
Slide 13: Overview - Patient Administration System (PAS)
Overview - Patient Administration System (PAS) A critical component of hospital IT infrastructure, providing administrative (non-clinical) functionality Overview of a PAS Core PAS Functionality • Foundation of hospital IT systems, capturing key patient and Patient Master Index Inpatient Management a
Slide 14: Market Dynamics and TAM Expansion
Market Dynamics and TAM Expansion As hospitals look towards replacing legacy PAS, there will be growing adoption of integrated EPR solutions Opportunity to deliver an alternative to legacy PAS & EPR Market Dynamics systems across all 145 UK Trusts UK • Minimal PAS innovation resulted in most incumbe
Slide 15: Establishing a Modern, Modular EPR Offering
Establishing a Modern, Modular EPR Offering Leveraging the Miya Precision platform along with Silverlink PCS PAS, Alcidion can deliver a cloud-native modern, modular, open architecture, EPR platform taking on the major global incumbents • Alcidion has a clear roadmap to become a leading provider of
Slide 16: “Built for Clinicians”
“Built for Clinicians” Leveraging the Miya Precision platform along with Silverlink PAS, Alcidion can ultimately deliver a modern, modular EPR platform taking on the major global incumbents Partner Products Alcidion Platform Modern, Modular Alcidion EPR Platform 3rd -Party Products Silverlink Platfo
Slide 17: Value Proposition of our Modular EPR
Value Proposition of our Modular EPR Alcidion’s EPR offering solves several customer pain points and market challenges Incumbent EPR Providers EPR • Primarily on premise or data centre deployments ✓ Full cloud-first EPR solution; 99.9% fail-over resilience Cloud Native • Progressively developing clo
Slide 18: Our EPR Strategy is aligned with UK NHSX
Our EPR Strategy is aligned with UK NHSX Sonia Patel, Chief Information Officer at NHSX: “Electronic Patient Record systems are the building blocks of good digital healthcare, but they are also complex and expensive to procure”. • NHSX: Joint unit of NHS England and the Department of Health and “At
Slide 19: Expanding Alcidion’s Market Penetration
Expanding Alcidion’s Market Penetration (UK Near-Term Focus) Material revenue opportunity driven by modular product upsell, along with new customer wins Alcidion NHS penetration in UK Market Contract Size Upside Potential Total Acute 38 (~26%) 145 Approx. • Current EPR offerings based on legacy tech
Slide 20: Silverlink Overview
rs ALCIDION r | Silverlink Overview
Slide 21: Silverlink Snapshot
Silverlink Snapshot Trusted provider of PAS software to 12 NHS Trusts, supported by 11 experienced healthcare professionals Business Overview • Founded in 1994, Silverlink is one of the largest and last remaining specialist (standalone) PAS providers servicing the UK NHS market – Flagship product, P
Slide 22: Customer Overview
Customer Overview • Long-standing customer relationships with 12 NHS Trusts across approximately 50 different locations • PAS market based on credibility and trust; high barriers to entry and long sales cycles resulting in very sticky customer relationships • All customers have been using Silverlink
Slide 23: Silverlink Key Financials & Deal Terms
Silverlink Key Financials & Deal Terms Financial Overview1,2 Key Acquisition Terms • 95% recurring revenue, with Licence / Maintenance & Support • Acquisition price in cash of £33.0M (A$61.1M1) fees invoiced quarterly in advance for most customers – £30.0M (A$55.5M1) payable upfront; and • 92%+ gros
Slide 24: Strong Organic Growth
Strong Organic Growth
Slide 25: New Contract: $23M+ initial TCV
New Contract: $23M+ initial TCV Commonwealth of Australia as part of consortium with Leidos Australia • Announced on 3 December 2021, Alcidion, as part of a Consortium led by Leidos, have signed a major healthcare IT project to capture data & support clinical decision making for the Commonwealth of
Slide 26: Ongoing Q2’22 Sales Momentum & Deployments
Ongoing Q2’22 Sales Momentum & Deployments Recent Contract Wins Successful Deployments • New contract with TCV of $1.8M over 3 years, won • As of 11 November 2021, ExtraMed software ‘live’ via competitive tender process Sydney Salford NHS • Part of UK’s first ‘Digital Control Centre’; £25m IT LHD •
Slide 27: Outlook
Outlook Expanding pipeline underpinned by larger market opportunity and customer demand Miya Precision + PCS (EPR Strategy) Outlook • PCS provides Alcidion with immediate IP and expert • Contracted revenue for FY22 of $18.7M at 30 November knowledge of the UK PAS market 2021, with a further $2.1M of
Slide 28: Capital Raising
Capital Raising
Slide 29: Capital Raising Overview
Capital Raising Overview Transaction Overview Offer Size A$55M, via the issue of approximately 220 million fully paid ordinary shares • Placement to raise A$30M via the issue of approximately 120 million fully paid ordinary shares, issued under Alcidion’s existing Placement capacity per ASX Listing
Slide 30: Capital Raising – Indicative Timetable
Capital Raising – Indicative Timetable1 Key Events Key Dates Trading halt and announcement of Placement and Underwritten ANREO Tuesday, 7 December 2021 Announcement of results of Institutional Entitlement Offer Thursday, 9 December 2021 Trading Halt is lifted and trading resumes on an “ex-entitlemen
Slide 31: Appendix
Appendix
Slide 32: Alcidion PAS & EPR Expertise
Alcidion PAS & EPR Expertise Senior Leadership has deep and extensive expertise in developing, selling & implementing PAS solutions Kate Quirke – Group Managing Director • Successful history selling PAS to the Australian market including multiple statewide procurements • Lead the process to align i.
Slide 33: Key Risks, Underwriting & Offer Restrictions
Key Risks, Underwriting & Offer Restrictions
Slide 34: Important Notice and Disclaimer
Important Notice and Disclaimer Item Description This investor presentation (“Presentation”) has been prepared by Alcidion Group Limited (ACN 143 142 410) (“Alcidion” or the “Company”) and is dated 7 December 2021. This Presentation has been prepared in relation to a proposed capital raising ("Capit
Slide 35: Important Notice and Disclaimer
Important Notice and Disclaimer Item Description Past Performance Past performance and pro-forma historical information in this Presentation is given for illustrative purposes only and should not be relied upon (and is not) an indication of future performance including future share price information
Slide 36: Key Risks - Specific
Key Risks - Specific Risk Description The Company has entered into an underwriting agreement with Henslow Pty Ltd and Canaccord Genuity (Australia) Limited (the “Underwriters”) under which the Underwriters have agreed to fully Funding Risk underwrite the Offer, subject to the terms and conditions of
Slide 37: Key Risks - Specific
Key Risks - Specific Risk Description Alcidion has historically focused on developing its platform and product and growing its customer base via the recruitment of sales, delivery, development, marketing and governance staff. While revenue Alcidion is loss making has grown over the past several year
Slide 38: Key Risks - General
Key Risks - General Risk Description The global economy, including each of the markets in which Alcidion operates, is in the midst of a pandemic relating to the novel coronavirus now known as COVID-19. The pandemic has led to the adoption of unprecedented preventative measures by Governments and oth
Slide 39: Equity Capital Raising Risk
Equity Capital Raising Risk Description The Company entered into an offer management and underwriting agreement with the Joint Lead Managers in respect of the Equity Capital Raising on 7 December 2021 (“Underwriting Agreement”). The Underwriter’s obligations under the Underwriting Agreement, includi
Slide 40: International Offer Restrictions
International Offer Restrictions Location Description WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission i
Slide 41: Glossary (Key Terms)
Glossary (Key Terms) Acronym Name Description Patient Administrative PAS Systems designed to manage the administrative aspects of patient care delivery such as patient identity management, attendance details, etc. System Electronic Patient Record EPR / EMR An EPR / EMR is a system designed to manage
Slide 42: “Making the right thing to do, the easiest thing to do”
Alcidion helps healthcare organisations harness the power of technology to create a clinically relevant environment with digitally enabled care… “Making the right thing to do, the easiest thing to do” 42
Slide 43: Slide 43
Alcidion Group — Investor Presentation (December 2021) on 6ix